B-intervention	0	9	Tamoxifen
O	10	13	for
O	14	17	the
O	18	28	prevention
O	29	31	of
O	32	38	breast
O	39	45	cancer
O	45	46	:
O	47	59	psychosocial
O	60	66	impact
O	67	69	on
O	70	75	women
O	76	89	participating
O	90	92	in
O	93	96	two
O	97	107	randomized
O	108	118	controlled
O	119	125	trials
O	125	126	.

O	127	130	The
O	131	138	purpose
O	139	141	of
O	142	146	this
O	147	152	study
O	153	156	was
O	157	159	to
O	160	168	evaluate
O	169	172	the
O	173	185	psychosocial
O	186	198	implications
O	199	201	of
O	202	211	tamoxifen
O	212	218	versus
B-control	219	226	placebo
O	227	229	in
B-eligibility	230	235	women
I-eligibility	236	239	who
I-eligibility	240	243	are
I-eligibility	244	246	at
I-eligibility	247	256	increased
I-eligibility	257	261	risk
I-eligibility	262	264	of
I-eligibility	265	271	breast
I-eligibility	272	278	cancer
O	278	279	.

O	280	283	The
B-total-participants	284	287	488
O	288	293	women
O	294	296	in
O	297	300	the
O	301	313	psychosocial
O	314	319	study
O	320	324	were
O	325	334	recruited
O	335	339	from
O	340	352	participants
O	353	355	in
O	356	359	two
O	360	367	placebo
O	367	368	-
O	368	378	controlled
O	378	379	,
O	380	386	double
O	386	387	-
O	387	392	blind
O	392	393	,
O	394	404	randomized
O	404	405	,
O	406	416	controlled
O	417	423	trials
O	424	428	that
O	429	441	investigated
O	442	445	the
O	446	454	efficacy
O	455	457	of
O	458	467	tamoxifen
O	468	470	in
O	471	474	the
O	475	485	prevention
O	486	488	of
O	489	495	breast
O	496	502	cancer
O	503	505	in
O	506	511	women
O	512	515	who
O	516	519	are
O	520	522	at
O	523	527	high
O	528	536	familial
O	537	541	risk
O	541	542	.

O	543	549	During
O	550	551	a
O	552	553	5
O	553	554	-
O	554	558	year
O	559	565	period
O	565	566	,
O	567	575	repeated
O	576	587	assessments
O	588	592	were
O	593	597	made
O	598	600	of
O	601	608	anxiety
O	608	609	,
O	610	623	psychological
O	624	632	distress
O	632	633	,
O	634	637	and
O	638	644	sexual
O	645	656	functioning
O	657	662	using
O	663	675	standardized
O	676	690	questionnaires
O	691	697	before
O	698	707	treatment
O	708	710	at
O	711	719	baseline
O	720	723	and
O	724	726	at
O	727	728	6
O	728	729	-
O	729	734	month
O	735	744	intervals
O	745	751	during
O	752	755	the
O	756	761	trial
O	761	762	.

O	763	776	Questionnaire
O	777	787	completion
O	788	792	over
O	793	794	5
O	795	800	years
O	801	804	was
O	805	809	good
O	809	810	,
O	811	815	with
O	816	818	71
O	818	819	.
O	819	820	1
O	820	821	%
O	822	824	of
O	825	830	women
O	831	840	returning
O	841	843	at
O	844	849	least
O	850	851	8
O	852	854	of
O	855	857	10
O	858	864	follow
O	864	865	-
O	865	867	up
O	868	879	assessments
O	879	880	.

O	881	889	Although
O	890	896	scores
O	897	901	from
O	902	913	individuals
O	914	920	showed
O	921	933	considerable
O	934	945	fluctuation
O	946	949	and
O	950	959	variation
O	960	964	over
O	965	969	time
O	969	970	,
B-outcome	971	978	changes
I-outcome	979	981	in
I-outcome	982	989	anxiety
O	989	990	,
B-outcome	991	995	mood
O	995	996	,
O	997	1000	and
B-outcome	1001	1007	sexual
I-outcome	1008	1019	functioning
O	1020	1024	were
O	1025	1028	not
O	1029	1039	associated
O	1040	1044	with
O	1045	1054	treatment
O	1055	1060	group
O	1060	1061	.

O	1062	1065	The
O	1066	1072	number
O	1073	1075	of
O	1076	1084	symptoms
O	1085	1093	reported
O	1094	1096	at
O	1097	1099	48
O	1100	1106	months
O	1107	1110	via
O	1111	1112	a
O	1113	1117	self
O	1117	1118	-
O	1118	1124	report
O	1125	1134	checklist
O	1135	1139	were
O	1140	1143	not
O	1144	1154	associated
O	1155	1159	with
O	1160	1169	treatment
O	1170	1175	group
O	1175	1176	,
O	1177	1180	but
B-outcome	1181	1190	vasomotor
I-outcome	1191	1199	symptoms
O	1200	1204	were
O	1205	1209	more
O	1210	1218	frequent
O	1219	1224	among
O	1225	1234	tamoxifen
O	1234	1235	-
O	1235	1242	treated
O	1243	1248	women
O	1248	1249	.

O	1250	1258	Symptoms
O	1259	1261	of
B-outcome	1262	1265	low
I-outcome	1266	1272	energy
O	1272	1273	,
B-outcome	1274	1280	breast
I-outcome	1281	1292	sensitivity
O	1292	1293	,
O	1294	1297	and
B-outcome	1298	1304	visual
I-outcome	1305	1313	blurring
O	1314	1318	were
O	1319	1327	reported
O	1328	1332	most
O	1333	1343	frequently
O	1344	1346	in
O	1347	1350	the
O	1351	1358	placebo
O	1359	1364	group
O	1364	1365	.

O	1366	1368	In
O	1369	1376	general
O	1376	1377	,
O	1378	1383	these
O	1384	1391	results
O	1392	1395	are
O	1396	1406	comparable
O	1407	1409	to
O	1410	1415	those
O	1416	1420	from
O	1421	1424	the
O	1425	1433	National
O	1434	1442	Surgical
O	1443	1451	Adjuvant
O	1452	1458	Breast
O	1459	1462	and
O	1463	1468	Bowel
O	1469	1476	Project
O	1477	1489	psychosocial
O	1490	1495	study
O	1496	1503	despite
O	1504	1515	differences
O	1516	1518	in
O	1519	1524	study
O	1525	1536	populations
O	1536	1537	,
O	1538	1549	methodology
O	1549	1550	,
O	1551	1554	and
O	1555	1566	instruments
O	1566	1567	.

O	1568	1571	The
O	1572	1576	long
O	1576	1577	-
O	1577	1581	term
O	1582	1585	use
O	1586	1588	of
O	1589	1598	tamoxifen
O	1599	1602	and
O	1603	1608	other
O	1609	1618	selective
O	1619	1627	estrogen
O	1628	1636	response
O	1637	1647	modulators
O	1648	1650	as
O	1651	1661	preventive
O	1662	1668	agents
O	1669	1671	in
O	1672	1676	high
O	1676	1677	-
O	1677	1681	risk
O	1682	1688	groups
O	1689	1692	has
O	1693	1697	been
O	1698	1708	questioned
O	1708	1709	,
O	1710	1713	but
O	1714	1716	we
O	1717	1722	found
O	1723	1725	no
O	1726	1734	evidence
O	1735	1737	of
O	1738	1747	treatment
O	1747	1748	-
O	1748	1755	related
O	1756	1760	side
O	1761	1768	effects
O	1769	1773	that
O	1774	1780	affect
O	1781	1786	women
O	1786	1787	'
O	1787	1788	s
O	1789	1801	psychosocial
O	1802	1805	and
O	1806	1812	sexual
O	1813	1824	functioning
O	1824	1825	.
